Weight & Metabolic
Do GLP-1s Work Differently in Older Adults?
The short answer
In the largest post hoc analyses available, weight loss and cardiometabolic improvements with tirzepatide were broadly similar in adults 65 and older compared with younger adults, and adverse event rates were not meaningfully higher. But older adults were more likely to stop treatment because of side effects, and almost none of the underlying trials were designed around this age group — they enrolled older adults incidentally, then sliced the data afterward. Dedicated trials built specifically to test sarcopenia risk, frailty, and physical function in older adults on these drugs are only just getting started, and the largest completed one so far enrolled 20 people.
Quick answers
- What is it?
- Whether GLP-1 medications work differently, or carry different risks, in older adults.
- Why are people interested in it?
- Older adults considering these drugs want to know if age changes how well they work or how safe they are.
- What has actually been studied?
- Post hoc analyses pooling data across seven tirzepatide obesity trials and the SURPASS diabetes trials by age group, plus a handful of small dedicated trials — the largest completed one enrolling only 20 people — built specifically around older adults.
- How strong is the evidence?
- Mostly post hoc subgroup analyses of trials not designed around age, showing broadly comparable efficacy and safety — but the dedicated research in this population is thin and just starting.
- What don't we know yet?
- Whether the pooled findings hold up in frailer, older-old populations, physical function and fall risk as directly measured outcomes, and outcomes specifically in adults over 80.
- Where can I read the original research?
- Sources at the bottom of this page: Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials and Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials.
The short answer: In the largest analyses available — post hoc slices of trials that weren't designed around age — tirzepatide produced weight loss and cardiometabolic improvements in adults 65 and older that were broadly comparable to what younger adults experienced, and overall adverse event rates weren't meaningfully higher. But older adults were more likely to stop treatment specifically because of side effects. And the honest caveat sits underneath all of it: these are subgroup analyses of trials that enrolled older adults along the way, not trials designed to test how the drugs perform in aging, frail, or sarcopenia-prone bodies. The dedicated research in that specific population is just beginning, and the largest completed trial purpose-built for it enrolled 20 people.
What the research shows
The pooled trial data: efficacy looks similar by age
A 2026 post hoc analysis pooled data across seven tirzepatide obesity trials — SURMOUNT-1 through -5 (including the 3-year SURMOUNT-1 extension), SURMOUNT-OSA, and SUMMIT — and compared outcomes in participants aged 65 and older against those under 65. Weight reduction and improvements in cardiometabolic risk factors and quality-of-life measures were described as "broadly comparable" between the two age groups. On safety, the analysis reported no clinically meaningful differences in adverse event rates between tirzepatide and placebo for older adults specifically, across gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and kidney, liver, and gallbladder-related events. The authors' conclusion was that no risks beyond those already inherent to older age were detected.
Glycemic control held up even without obesity as a driver
A separate 2025 post hoc analysis took a different slice: adults 65 and older with type 2 diabetes but a BMI under 30 — meaning weight loss wasn't the main lever — pooled across the SURPASS 1 through 5 trials. HbA1c reductions in this subgroup ranged from 1.97 to 2.10 percentage points, and notably didn't scale with dose the way the overall trial population's HbA1c response did. Weight loss in this subgroup was dose-proportional but numerically smaller than in the broader population. The same analysis found that older, non-obese participants were more likely to discontinue treatment due to adverse events than the general trial population, even though the overall rate of adverse events in this subgroup was still described as low.
A national subgroup check tells a similar story
A prespecified subgroup analysis of the Japan-based SURMOUNT-J trial (225 participants) examined tirzepatide outcomes by sex, age (under 65 versus 65 and older), and BMI category. Weight reduction was described as generally similar across these subgroups, and the proportion of participants achieving at least 5% weight loss was high across the board — though the published figures broke out sex and BMI comparisons in more granular detail than the age-specific numbers.
Why "similar in trials" isn't the same as "well studied"
None of the trials feeding these pooled analyses were designed around older adults. They were general obesity or diabetes trials that happened to enroll some participants over 65, and researchers went back afterward to check whether that subgroup behaved differently. A 2024 review focused specifically on obesity pharmacotherapy in older adults made this gap explicit: despite growing evidence of favorable efficacy and safety in the general population, "concise guidelines for older adults are not available," and the review called for trials that track not just weight loss but geriatric-specific endpoints — muscle mass preservation, bone quality, and fat distribution — in this age group directly.
The dedicated trials that do exist are small and just starting
Searching the clinical trial registry for studies built specifically around older adults on GLP-1 therapy turns up six trials. Most are either still recruiting, not yet recruiting, or barely underway: a Sheba Medical Center trial testing exercise and nutrition alongside semaglutide to reduce sarcopenia risk (60 participants, recruiting), a Wake Forest pilot on tirzepatide's effects on fat-free mass, bone, and physical function (40 participants, active but not recruiting), a Veru Inc. trial combining semaglutide with a muscle-preserving compound (200 participants, just started), and a Vanderbilt trial on HMB supplementation during semaglutide-associated weight loss (90 participants, not yet recruiting). Only two have completed: a University at Buffalo trial on preserving lean body mass in elderly patients on semaglutide (16 participants), and a University of Texas San Antonio trial on physical function and aging biomarkers (20 participants) — the same pilot referenced above, which found no significant change in bone density despite meaningful weight loss.
What we don't know yet
Whether the pooled trial findings hold up in frailer, older-old populations. The post hoc analyses draw from trials that generally required participants to be well enough to complete a structured drug trial. People with significant frailty, multiple comorbidities, or cognitive impairment are underrepresented or excluded by design.
Physical function and fall risk as directly measured outcomes. The pooled safety analyses checked whether falls and fractures occurred at different rates, but grip strength, gait speed, and other functional measures specific to aging bodies were not the trials' primary focus.
Adults over 80. Most "older adult" subgroup cutoffs in these analyses are set at 65, which is a wide net. Data specific to adults in their 80s and 90s is close to absent.
Why older adults discontinue more often, and whether that's manageable. The SURPASS post hoc analysis found higher adverse-event-driven discontinuation in older, non-obese adults, but didn't identify which side effects drove it or whether dose adjustment changes the pattern.
Sarcopenic obesity outcomes specifically. The trials purpose-built to test muscle and bone preservation in older adults on these drugs are recruiting now, not reporting results yet. The current evidence base in this exact population is a handful of trials with fewer than 40 participants each.
Sources
- Alfaris N, Kushner RF, Li J, et al. Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials. Diabetes, Obesity & Metabolism, 2026;28(9):8072–8083. DOI
- Rasouli N, Wilding JPH, Kwan AYM, et al. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials. Diabetes Therapy, 2025;16(4):701–715. DOI
- Žižka O, Haluzík M, Jude EB. Pharmacological Treatment of Obesity in Older Adults. Drugs & Aging, 2024;41(11):881–896. DOI
- Dinkla L, Beavers KM, Robbins R, et al. Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial analysis. Frontiers in Aging, 2025;6:1691007. DOI
- Yokote K, Fukushima Y, Shingaki T, et al. Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial. Diabetes, Obesity & Metabolism, 2026;28(2):1278–1287. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Weight & Metabolism · Aging & Longevity | Evidence Index: semaglutide · tirzepatide
Sources
- Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials
- Diabetes, Obesity & Metabolism, 2026 · DOI
- Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials
- Diabetes Therapy, 2025 · DOI
- Pharmacological Treatment of Obesity in Older Adults
- Drugs & Aging, 2024 · DOI
- Bone mineral density and turnover response to GLP-1 receptor agonists in older adults: a 20-week pilot trial
- Frontiers in Aging, 2025 · n=20 · DOI
- Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: SURMOUNT-J subgroup analysis
- Diabetes, Obesity & Metabolism, 2026 · n=225 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.